$6.39 $0.10 (1.6%)

09:30 AM EDT on 06/18/19

Galmed Pharmaceuticals (NASDAQ:GLMD)

CAPS Rating: 1 out of 5

Current Price $6.39 Mkt Cap $173.3M
Open $6.39 P/E Ratio 0.00
Prev. Close $6.29 Div. (Yield) $0.00 (0.0%)
Daily Range $6.39 - $6.39 Volume 700
52-Wk Range $5.48 - $9.37 Avg. Daily Vol.

Caps

How do you think NASDAQ:GLMD will perform against the market?

Add Stock to CAPS Watchlist

All Players

18 Outperform
11 Underperform
 

All-Star Players

6 Outperform
8 Underperform
 

Wall Street

1 Outperform
0 Underperform
 

Top NASDAQ:GLMD Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Top Bull Pitch

There are no pitches that meet the Top Bull criteria. Explain

If this upsets you, start recommending pitches below!

nevercontent (77.87)
Submitted October 22, 2015

Speculation on buyouts aside, I think it’s clear that Galmed has a long road ahead of it. It has to successfully complete its phase 2 trials, then fund and complete phase 3 trials, then obtain regulatory approval, then undergo a significant… More

NASDAQ:GLMD VS S&P 500 (SPY)

NASDAQ:GLMD Summary

Fools bullish on NASDAQ:GLMD are also bullish on:

Fools bearish on NASDAQ:GLMD are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about GLMD.

Recs

0
Member Avatar sampson01 (< 20) Submitted: 6/9/2016 12:05:33 AM : Outperform Start Price: $4.36 NASDAQ:GLMD Score: +6.54

Arrest and Arrive studies will both show positive results and ultimately will lead to a buy out from Gilead.

Recs

1
Member Avatar nevercontent (77.87) Submitted: 10/22/2015 3:15:54 PM : Underperform Start Price: $9.54 NASDAQ:GLMD Score: +75.99

Speculation on buyouts aside, I think it’s clear that Galmed has a long road ahead of it. It has to successfully complete its phase 2 trials, then fund and complete phase 3 trials, then obtain regulatory approval, then undergo a significant transformation from a research organization, and then go on to succeed in a medical niche whose size isn’t really well understood. It's hard to know how much capital (read shareholder dilution) all of that will require. And even then, the company will likely only have about 5 years of regulatory exclusivity before generics begin moving in, and presumably it’ll be funneling a lot of that revenue into more trials for expanded usage and additional conditions and diseases.

Recs

0
Member Avatar jlziebelman (< 20) Submitted: 9/23/2015 3:58:49 PM : Outperform Start Price: $8.62 NASDAQ:GLMD Score: -77.29

research results on liver treatment

Leaderboard

Find the members with the highest scoring picks in GLMD.

Score Leader

DavidSobel

DavidSobel (< 20) Score: +336.19

The Score Leader is the player with the highest score across all their picks in GLMD.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
nevercontent 77.87 10/22/2015 Underperform 3Y $9.54 -33.02% +42.97% +75.99 1 Comment
TMFGBudwell 51.01 6/14/2018 Underperform 5Y $18.00 -64.50% +5.06% +69.56 0 Comment
BlindSkuirrel 29.83 5/20/2014 Underperform 3Y $7.10 -10.00% +55.65% +65.65 0 Comment
roolbreakers 98.81 7/13/2018 Underperform 5Y $14.86 -57.01% +4.83% +61.84 0 Comment
deepcrisis 99.66 7/12/2018 Underperform 5Y $14.02 -54.42% +5.26% +59.68 0 Comment
IWantToBeatBabo 99.94 7/3/2018 12/26/2018 Underperform NS $11.81 -45.89% +7.43% +53.32 0 Comment
WildShaman 93.64 7/5/2018 Underperform 5Y $11.69 -45.34% +7.70% +53.04 0 Comment
zzlangerhans 99.80 12/13/2017 Underperform 1Y $8.86 -27.88% +9.77% +37.65 0 Comment
downwithpumpers 99.27 8/4/2017 Underperform 5Y $6.92 -7.66% +18.43% +26.09 0 Comment
dusand 99.71 2/8/2019 Underperform 5Y $7.21 -11.37% +8.99% +20.36 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackMaximGroup 65.39 4/23/2014 Outperform NS $9.65 -33.78% +56.08% -89.87 0 Comment

Advertisement